BACKGROUND: Tumor resistance to chemoradiation therapy is partly attributed to the presence of apoptosis-resistant cancer stem cells (CSCs). Chemoradiation therapy can enrich CSCs by killing apoptosis-susceptible cancer cells. AIM: Our preliminary study showed chemoradiation-resistant pancreatic cancer cells to have some CSC characteristics, and to undergo epithelial-mesenchymal transition (EMT); we aimed to verify that study's implication that chemoradiation-resistant subpopulations are enriched with "stem-cell-like" tumor cells, which may be linked to EMT. METHODS: Four pancreatic cancer cell lines were cultured in gemcitabine with synchronous radiotherapy to obtain resistant subpopulations. Morphological changes were observed under microscope; migration and invasiveness were assessed by Transwell tests. Protein expression was determined by immunoblotting. Pancreatic CSC markers were studied using fluorescence-activated cell sorting analyses. Colony-formation tests, tumor sphere formation assays, and tumor xenografts in BALB/C nude mice were used to evaluate "stemness" in resistant cells. RESULTS: Resistant cells expressed more antiapoptotic protein Bcl-2, apoptosis-inhibitory protein survivin, and stem cell markers Oct4, ABCG2, CD24, and CD133, were more tumorigenic in vitro and in vivo, and showed phenotypic and molecular changes consistent with EMT, including upregulation of vimentin and downregulation of E-cadherin. They were also more invasive and migratory. CONCLUSIONS: We found chemoradiation-resistant pancreatic cancer cells to be similar to CSCs and to undergo EMT, suggesting that chemoradiation resistance-induced EMT is linked to CSC generation.
BACKGROUND:Tumor resistance to chemoradiation therapy is partly attributed to the presence of apoptosis-resistant cancer stem cells (CSCs). Chemoradiation therapy can enrich CSCs by killing apoptosis-susceptible cancer cells. AIM: Our preliminary study showed chemoradiation-resistant pancreatic cancer cells to have some CSC characteristics, and to undergo epithelial-mesenchymal transition (EMT); we aimed to verify that study's implication that chemoradiation-resistant subpopulations are enriched with "stem-cell-like" tumor cells, which may be linked to EMT. METHODS: Four pancreatic cancer cell lines were cultured in gemcitabine with synchronous radiotherapy to obtain resistant subpopulations. Morphological changes were observed under microscope; migration and invasiveness were assessed by Transwell tests. Protein expression was determined by immunoblotting. Pancreatic CSC markers were studied using fluorescence-activated cell sorting analyses. Colony-formation tests, tumor sphere formation assays, and tumor xenografts in BALB/C nude mice were used to evaluate "stemness" in resistant cells. RESULTS: Resistant cells expressed more antiapoptotic protein Bcl-2, apoptosis-inhibitory protein survivin, and stem cell markers Oct4, ABCG2, CD24, and CD133, were more tumorigenic in vitro and in vivo, and showed phenotypic and molecular changes consistent with EMT, including upregulation of vimentin and downregulation of E-cadherin. They were also more invasive and migratory. CONCLUSIONS: We found chemoradiation-resistant pancreatic cancer cells to be similar to CSCs and to undergo EMT, suggesting that chemoradiation resistance-induced EMT is linked to CSC generation.
Authors: Anthony D Yang; Fan Fan; E Ramsay Camp; George van Buren; Wenbiao Liu; Ray Somcio; Michael J Gray; Haiyun Cheng; Paulo M Hoff; Lee M Ellis Journal: Clin Cancer Res Date: 2006-07-15 Impact factor: 12.531
Authors: Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone Journal: Cancer Res Date: 2007-02-01 Impact factor: 12.701
Authors: Monika Olempska; Patricia Alice Eisenach; Ole Ammerpohl; Hendrik Ungefroren; Fred Fandrich; Holger Kalthoff Journal: Hepatobiliary Pancreat Dis Int Date: 2007-02
Authors: Cecilia Sahlgren; Maria V Gustafsson; Shaobo Jin; Lorenz Poellinger; Urban Lendahl Journal: Proc Natl Acad Sci U S A Date: 2008-04-21 Impact factor: 11.205
Authors: Shu Zhang; Curt Balch; Michael W Chan; Hung-Cheng Lai; Daniela Matei; Jeanne M Schilder; Pearlly S Yan; Tim H-M Huang; Kenneth P Nephew Journal: Cancer Res Date: 2008-06-01 Impact factor: 12.701
Authors: Cristiana Pistol Tanase; Ana Iulia Neagu; Laura Georgiana Necula; Cristina Mambet; Ana-Maria Enciu; Bogdan Calenic; Maria Linda Cruceru; Radu Albulescu Journal: World J Gastroenterol Date: 2014-08-21 Impact factor: 5.742
Authors: Yue Zhao; Lu Zhao; Ivan Ischenko; Qi Bao; Bettina Schwarz; Hanno Nieß; Yan Wang; Andrea Renner; Josef Mysliwietz; Karl-Walter Jauch; Peter J Nelson; Joachim W Ellwart; Christiane J Bruns; Peter Camaj Journal: Target Oncol Date: 2015-02-03 Impact factor: 4.493
Authors: John R Ohlfest; David M Zellmer; Jayanth Panyam; Suresh Kumar Swaminathan; Seunguk Oh; Nate N Waldron; Shoko Toma; Daniel A Vallera Journal: Drug Deliv Transl Res Date: 2013-04 Impact factor: 4.617
Authors: Suresh Kumar Swaminathan; Lin Niu; Nate Waldron; Steve Kalscheuer; David M Zellmer; Michael R Olin; John R Ohlfest; Daniel A Vallera; Jayanth Panyam Journal: Drug Deliv Transl Res Date: 2013-04 Impact factor: 4.617
Authors: Lilian E van Vlerken; Christine M Kiefer; Chris Morehouse; Ying Li; Chris Groves; Susan D Wilson; Yihong Yao; Robert E Hollingsworth; Elaine M Hurt Journal: Stem Cells Transl Med Date: 2012-12-27 Impact factor: 6.940